Abstract:Motivated by increasing pressure for decision makers to shorten the time required to evaluate the efficacy of a treatment such that treatments deemed safe and effective can be made publicly available, there has been substantial recent interest in using an earlier or easier to measure surrogate marker, $S$, in place of the primary outcome, $Y$. To validate the utility of a surrogate marker in these settings, a commonly advocated measure is the proportion of treatment effect on the primary outcome that is explained by the treatment effect on the surrogate marker (PTE). Model based and model free estimators for PTE have also been developed. While this measure is very intuitive, it does not directly address the important questions of how $S$ can be used to make inference of the unavailable $Y$ in the next phase clinical trials. In this paper, to optimally use the information of surrogate S, we provide a framework for deriving an optimal transformation of $S$, $g_{opt}(S)$, such that the treatment effect on $g_{opt}(S)$ maximally approximates the treatment effect on $Y$ in a certain sense. Based on the optimally transformed surrogate, $g_{opt}(S)$, we propose a new measure to quantify surrogacy, the relative power (RP), and demonstrate how RP can be used to make decisions with $S$ instead of $Y$ for next phase trials. We propose nonparametric estimation procedures, derive asymptotic properties, and compare the RP measure with the PTE measure. Finite sample performance of our estimators is assessed via a simulation study. We illustrate our proposed procedures using an application to the Diabetes Prevention Program (DPP) clinical trial to evaluate the utility of hemoglobin A1c and fasting plasma glucose as surrogate markers for diabetes.

Evaluation of Surrogate Endpoints Using Information-Theoretic Measure of Association Based on Havrda and Charvat Entropy

Evaluating time-to-event surrogates for time-to-event true endpoints: an information-theoretic approach based on causal inference

Assessing heterogeneity in surrogacy using censored data

Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity

A new proportion measure of the treatment effect captured by candidate surrogate endpoints

An information‐theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: Application to vaccine evaluation

Evaluating Surrogate Marker Information using Censored Data

Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy

A Reflection on the Impact of Misspecifying Unidentifiable Causal Inference Models in Surrogate Endpoint Evaluation

Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm

CRITERIA FOR MULTIPLE SURROGATES

Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect

Towards Optimal Use of Surrogate Markers to Improve Power

Information Recovery in a Study with Surrogate Endpoints

Establishing and Using Threshold of Surrogate Endpoint in Relation to Clinical Endpoint

Sufficient conditions for concluding surrogacy based on observed data.

Surrogate Markers and Joint Models for Longitudinal and Survival Data

Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level a Bayesian approach and application to surrogate endpoint evaluation

Criteria for surrogate end points

On the Evaluation of Surrogate Markers in Real World Data Settings

Surrogacy Validation for Time-to-Event Outcomes with Illness-Death Frailty Models